Huons Receives IND Approval for Phase 2 Clinical Trial of Dry Eye Disease Drug 'HUC1-394'
Peptide-Based Ophthalmic Solution
Expected to Control Inflammation and Improve Keratoconjunctivitis
Huons has entered the next phase of clinical trials for the development of a new mechanism dry eye disease drug.
On March 12, Huons announced that it had received approval from the Ministry of Food and Drug Safety on the previous day (March 11) for the Phase 2 clinical trial plan (IND) of 'HUC1-394', a new drug candidate for the treatment of dry eye disease.
HUC1-394 is a peptide-based ophthalmic solution introduced by Huons from Novacell Technology Co., Ltd.
This substance selectively binds to and activates the formyl peptide receptor 2 (FPR2), a receptor involved in the resolution process of inflammation in the body. By not only suppressing inflammation but also properly terminating the inflammatory response and restoring damaged tissue, it is expected to fundamentally improve dry eye disease by ameliorating keratoconjunctivitis (inflammation of the cornea and conjunctiva).
Last year, Huons demonstrated the safety and tolerability of HUC1-394 through a Phase 1 clinical trial involving 60 healthy adults. At that time, no serious adverse events (SAEs) occurred as a result of single and repeated administration, providing sufficient grounds for subsequent clinical trials.
With this Phase 2 clinical trial approval, Huons will conduct the study at major medical institutions, including Severance Hospital of Yonsei University College of Medicine, administering the trial to 150 patients with dry eye disease. The trial will be conducted using a multi-center, randomized, double-masked (RCT) design to confirm the safety and efficacy of HUC1-394 and to explore the optimal dosage regimen.
Huons expects that HUC1-394 will effectively control inflammation, the main cause of dry eye disease, while also minimizing the potential for side effects.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kyungmi Park, Executive Vice President of R&D at Huons, stated, "Through the analysis of the Phase 1 clinical trial results for HUC1-394, we have confirmed the validity of proceeding with subsequent clinical trials." She added, "Starting with this IND approval, we will do our best to carry out Phase 2 clinical trials without delay, so that we can provide a new treatment option for patients suffering from dry eye disease."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.